# Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

> **NCT04457687** · — · AVAILABLE · sponsor: **Eisai Inc.**

## Conditions studied

- Epilepsies, Myoclonic
- Drug Resistant Epilepsy

## Interventions

- **DRUG:** Lorcaserin

## Key facts

- **NCT ID:** NCT04457687
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04457687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04457687, "Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04457687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*